Melatonin is often used for children with sleep disorders, though Australian guidelines recommend caution and prioritize behavioral approaches first.
TGA approval limits
The Therapeutic Goods Administration has approved melatonin only for short-term use in adults over 55 with insomnia. No product containing melatonin is approved for children in Australia. This regulatory gap creates challenges for general practitioners, as parents frequently request help for sleep issues, yet the regulator’s position remains firm.
Despite the lack of approval, many clinicians still prescribe it off-label for conditions like autism spectrum disorder or ADHD, where sleep disruption is common. The TGA’s stance does not prevent prescriptions but requires doctors to justify their decisions and outline potential risks.
Dosage and timing considerations
Most children respond well to doses between 1 mg and 6 mg, taken 30 to 60 minutes before bedtime. Higher doses do not guarantee better results and may lead to daytime drowsiness. Timing plays an equally important role: administering it too early can cause premature sleepiness, while delaying it may push its effects past midnight.
This variability makes standardized dosing unreliable. Doctors typically start with 1 mg for preschoolers and 2 mg for older children, adjusting only after reviewing sleep diaries for at least two weeks.
Behavioral strategies remain the priority
Guidelines advise trying sleep hygiene practices before considering melatonin. Consistent bedtimes, calming routines, and reducing screen time an hour before bed often resolve sleep problems within weeks. If these methods fail, melatonin may be introduced—but never as the sole solution.
Related: Weight Loss Tips That Actually Work!
When used, the medication is intended as a temporary measure. The aim is to stabilize sleep long enough for behavioral changes to take effect.
Off-label prescribing is not unusual in pediatrics, particularly for conditions like asthma or epilepsy, where evidence develops faster than formal approvals. Melatonin differs because its long-term effects on developing brains are not well studied. Most research spans only a few weeks, leaving safety beyond six months uncertain.
General practitioners must weigh immediate benefits against potential risks. The TGA’s position is not a prohibition but a reminder that melatonin should not be the first option and that behavioral interventions must come first.
When to seek further help or discontinue use
If a child’s sleep does not improve after six weeks of combined behavioral and melatonin therapy, referral to a pediatric sleep specialist is advised. Persistent insomnia may indicate underlying issues such as anxiety, restless legs syndrome, or sleep apnea, which melatonin cannot address.
Discontinuing melatonin can be difficult for some children. Rebound insomnia may occur for a few nights, though others adjust without problems. Reducing the dose gradually over a week can help, but no standard protocol exists. The lack of TGA approval also means there is no official guidance on withdrawal.
For now, the advice to doctors is clear: use melatonin cautiously, maintain thorough records, and keep behavioral strategies central to treatment. For families struggling with chronic sleep issues, patience and consistency often yield the best results.
